Home Current News South Korea pharma Celltrion’s COVID test gets U.S. emergency use authorisation

South Korea pharma Celltrion’s COVID test gets U.S. emergency use authorisation

17

South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisationSouth Korea’s Celltrion Inc said on Monday it has received emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates. Celltrion said Sampinute delivers coronavirus test results within 10 minutes, with a sensitivity of around 94%. The authorisation came three months after requesting approval in late July and the product has already been launched in the United States in August, according to the company statement.

Source: yahoo.com/news